COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome - Summary - MDSpire

COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome

  • By

  • Maria Teresa Lupo-Stanghellini

  • Elisabetta Xue

  • Sara Mastaglio

  • Chiara Oltolini

  • Piera Angelillo

  • Carlo Messina

  • Simona Piemontese

  • Stefania Girlanda

  • Francesca Farina

  • Lorenzo Lazzari

  • Maria Pia Cicalese

  • Federico Erbella

  • Raffaella Greco

  • Massimo Locatelli

  • Raffaella Milani

  • Jacopo Peccatori

  • Consuelo Corti

  • Sarah Marktel

  • Andrea Assanelli

  • Fabio Ciceri

  • June 30, 2021

  • 0 min

Share

Objective:

To evaluate the outcomes of COVID-19 in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) between February 23 and April 27, 2020.

Key Findings:
  • 24 out of 254 patients reported symptoms compatible with COVID-19.
  • Six patients tested positive for COVID-19 via PCR; three were asymptomatic and did not require hospitalization.
  • Three hospitalized patients required respiratory support but did not develop severe complications like ARDS.
Interpretation:

The study suggests that HSCT recipients can have favorable outcomes with COVID-19, indicating a low incidence of severe disease and no fatalities, which may inform clinical management strategies.

Limitations:
  • Small sample size limits the ability to generalize findings and may introduce bias due to the observational nature of the study.
Conclusion:

Overall, HSCT patients showed a favorable outcome in COVID-19 infection, with effective management and recovery observed in all cases, highlighting the need for continued monitoring and tailored treatment strategies.

Original Source(s)

COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome

  • by Maria Teresa Lupo-Stanghellini, Elisabetta Xue, Sara Mastaglio, Chiara Oltolini, Piera Angelillo, Carlo Messina, Simona Piemontese, Stefania Girlanda, Francesca Farina, Lorenzo Lazzari, Maria Pia Cicalese, Federico Erbella, Raffaella Greco, Massimo Locatelli, Raffaella Milani, Jacopo Peccatori, Consuelo Corti, Sarah Marktel, Andrea Assanelli, Fabio Ciceri

  • June 30, 2021

Related Content

Generalizability of anti–SARS-CoV-2 seroprevalence estimates to the Montréal pediatric population: a comparison between 2 weighting methods

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease